• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Informing Treatment Decisions Using a 14-Gene Assay in Early Non-Small Cell Lung Cancer

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

ASCO 2025: Oncology Pathway Tools Show Consistent Usage Across Patient Groups

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status....

NCPA Fly-In Amplifies Pharmacists’ Voice on Capitol Hill: Advocacy, Access, and the Fight for Fair Reimbursement

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles National Community Pharmacists Association President Jeff Harrell, PharmD, shares insights from this year’s event, highlighting its growing impact, the importance of engaging with policymakers, and the urgent issues facing independent...

FDA Grants Interchangeability Designation to Hadlima, a Biosimilar for Humira

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions. Read More

ASCO 2025: Quadruplet Therapy Shows Promise in Transplant-Ineligible Multiple Myeloma

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM) from the CEPHEUS trial. Read More

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors. Read More
« Older Entries
Next Entries »

Recent Content

  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT